文献速递特殊人群用药抗菌药物管理

刚果基桑加尼孕妇疟疾预防:甲氟喹与磺胺多辛-乙胺嘧啶随机临床试验

Efficacy and safety of malarial prophylaxis with mefloquine during pregnancy in Kisangani, Democratic Republic of Congo: A randomized clinical trial.
PubMed 文献 · Br J Clin Pharmacol · 2021-01-26

在疟疾高传播且磺胺多辛-乙胺嘧啶耐药的刚果基桑加尼,单盲随机试验比较甲氟喹分次随餐与磺胺多辛-乙胺嘧啶间歇性预防治疗孕妇的效果与耐受性。甲氟喹未显著增加副作用,并显著降低胎盘疟疾、母体外周血症和低出生体重风险。

要点

  • 甲氟喹分次随餐方案较磺胺多辛-乙胺嘧啶显著降低胎盘疟疾风险(RR 0.4315)。
  • 甲氟喹显著降低母体外周血症风险(RR 0.4397)。
  • 甲氟喹显著降低低出生体重风险(RR 0.4708)。

核心结论

  • 甲氟喹分次随餐方案在保持疗效的同时,耐受性较磺胺多辛-乙胺嘧啶有所提高。
  • 甲氟喹间歇性预防治疗可降低胎盘疟疾、母体外周血症和低出生体重风险。
  • 甲氟喹可作为孕妇间歇性预防治疗的良好替代方案。

研究设计与样本

  • 比较两种孕妇间歇性预防治疗方案:4剂磺胺多辛-乙胺嘧啶 vs 2剂甲氟喹分次随餐。

主要发现

  • 甲氟喹组与磺胺多辛-乙胺嘧啶组主要副作用无统计学差异(Fisher精确检验=0.5014)。
  • 甲氟喹显著降低胎盘疟疾风险(RR 0.4315,95%CI 0.2201-0.8460)。
  • 甲氟喹显著降低母体外周血症风险(RR 0.4397,95%CI 0.2377-0.8132)。
  • 甲氟喹显著降低低出生体重风险(RR 0.4708,95%CI 0.2455-0.9029)。

临床怎么用

  • 在磺胺多辛-乙胺嘧啶耐药的疟疾高传播区,孕妇间歇性预防治疗可考虑甲氟喹分次随餐方案。
  • 甲氟喹分次随餐给药可能提高耐受性,但需结合当地耐药情况和患者个体因素评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Kisangani is an area with intense malaria transmission and sulfadoxine-pyrimethamine resistance. Alternative antimalaria prophylaxis medication and protocols are needed, particularly with pregnant individuals. In this study, we compare the tolerance and effectiveness of mefloquine regimen as a split dose with a meal vs. sulfadoxine-pyrimethamine for the intermittent preventive treatment in pregnant individuals in Kisangani. METHODS: This study was conducted from 15 May to 30 November 2019 as a single-blind, randomized clinical trial comparing 2 regimens of intermittent preventive treatment during pregnancy. The first regimen consisted of 4 doses of sulfadoxine-pyrimethamine, and the second of 2 doses of mefloquine taken as a split dose with meal. RESULTS: The occurrence of major or minor side-effects among patients treated with mefloquine and those treated with sulfadoxine-pyrimethamine were not statistically significant (major side effects: Fisher exact = 0.5014; minor side effects: P = .0961). Intermittent preventive treatment using mefloquine significantly reduced the risk of placental malaria (risk ratio [RR]: 0.4315, 95% confidence interval [CI]: 0.2201-0.8460), maternal peripheral parasitaemia (RR: 0.4397, 95% CI: 0.2377-0.8132) and low birth weight (RR: 0.4708, 95% CI: 0.2455-0.9029). CONCLUSION: Splitting dose and intake with a meal increased mefloquine tolerability while keeping its efficacy higher compared to sulfadoxine-pyrimethamine. Intermittent preventive treatment during pregnancy using mefloquine reduces the risk of placental malaria, maternal peripheral parasitaemia and low birth weight, compared to sulfadoxine-pyrimethamine. Thus, mefloquine is a good alternative to intermittent preventive treatment in pregnancy.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Labama Otuli N, Marini Djang'eing'a R, Losimba Likwela J, et al. Efficacy and safety of malarial prophylaxis with mefloquine during pregnancy in Kisangani, Democratic Republic of Congo: A randomized clinical trial. Br J Clin Pharmacol. 2021. PMID: 33398890. doi:10.1111/bcp.14720

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。